Objective-Previous proteomics experiments have demonstrated that several proteins are differentially expressed in vulnerable human carotid plaques compared with stable plaques. This study aims to investigate the prognostic value of 13 such circulating biomarkers in patients with coronary artery disease. Approach and Results-Between 2008 and 2011, 768 patients who underwent coronary angiography for acute coronary syndrome or stable angina pectoris were included in a prospective biomarker study. Plasma concentrations of 13 biomarkers were measured in 88 patients who experienced a major adverse cardiovascular event (MACE) within 1 year and 176 control patients without MACE who were matched on age, sex, and number of diseased coronary vessels. MACE comprised all-cause mortality, acute coronary syndrome, unplanned coronary revascularization, and stroke. After adjustment for established cardiovascular risk factors, osteoglycin (OGN; odds ratio per SD increase in ln-transformed OGN, 1.53; 95% confidence interval, 1.11-2.11; P=0.010) and neutrophil gelatinase-associated lipocalin/matrix metalloproteinase 9 (NGAL/MMP9; odds ratio per SD increase in ln-transformed NGAL/MMP9, 1.37; 95% confidence interval, 1.01-1.85; P=0.042) complex were independently associated with MACE during follow-up. These associations were independent of C-reactive protein levels. Adding OGN or NGAL/MMP9 to a model containing conventional risk factors did not significantly improve discriminatory power (OGN: area under receiver operating characteristic curve, 0.75 versus 0.67; NGAL/MMP9: 0.73 versus 0.67) but did significantly improve risk reclassification (OGN: net reclassification index=0.29; 95% confidence interval, 0.05-0.53; P<0.019; NGAL/MMP9: net reclassification index=0.44; 95% confidence interval, 0.20-0.69; P<0.001). Conclusions-Circulating OGN and NGAL/MMP9 complex are promising biomarkers that are expressed in vulnerable atherosclerotic plaques and may have incremental value for prediction of MACE within 1 year after coronary angiography. (Arterioscler Thromb Vasc Biol. 2014;34:1078-1084.)
A therosclerosis and plaque destabilization leading to coronary thrombosis and acute coronary syndrome are the result of a heterogeneous process, involving vascular inflammation, endothelial dysfunction, and hypercoagulability. 1, 2 Blood biomarkers may reflect these pathophysiological constituents of coronary artery disease (CAD). Consequently, blood biomarker level may be associated with severity of CAD and thus predict occurrence of adverse cardiovascular events in CAD patients. Such associations have been demonstrated already for several biomarkers, such as C-reactive protein (CRP). [3] [4] [5] The main challenge in investigating which biomarkers are suitable for prediction of adverse cardiovascular events is that plasma contains >900 000 proteins. 6 A disadvantage of traditional research is that it tests each of the plasma proteins individually. Proteomics-based research has the potential to offer insight into the full complexity of atherosclerosis with its various components and may reveal novel biomarkers that have the ability to improve prediction of adverse events. 7 In a previous proteomic study, we have found several proteins to be differentially released by vulnerable hemorrhagic human carotid plaques when compared with stable fibrotic plaques. 8 The majority of these proteins, including aciculin, oncogene DJ1 (DJ1), microfibril-associated glycoprotein 4, osteoglycin (OGN), procollagen C proteinase enhancer 1, phosphatidylethanol-amine-binding protein 1, and peroxiredoxin 2, have not yet been investigated as prognostic biomarkers in CAD patients. In addition, evidence exists that neutrophil gelatinase-associated lipocalin (NGAL) and its NGAL/matrix metalloproteinase 9 (NGAL/MMP9) complex display increased expression in (unstable) atherosclerotic plaques. 9, 10 These proteins have also not yet been investigated as prognostic biomarkers in CAD patients.
We have performed a prospective, nested case-control study in a cohort of 768 patients undergoing coronary angiography to investigate whether plasma levels of the above-described novel protein biomarkers are associated with adverse cardiovascular events. We have also evaluated whether these biomarkers improve discrimination and risk reclassification.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Baseline Characteristics
Mean age of the patients was 64.9 (SD, 10.6) years, 77% were men, and 52% had acute coronary syndrome (Table 1) . Percutaneous coronary intervention was performed in 82% of the patients. The group of patients who experienced major adverse cardiovascular event (MACE) during follow-up displayed a higher prevalence of diabetes mellitus (27.3% versus 14.9%; P=0.016) and a tendency toward a higher prevalence of renal insufficiency (11.4% versus 4.6%; P=0.053) compared with the group of patients who did not had MACE. Other baseline characteristics did not display significant differences between cases and controls.
Associations With Cardiovascular Outcome
Plasma NGAL seemed to be normally distributed. Aciculin, DJ1, heat shock protein 27, microfibril-associated glycoprotein 4, NGAL/MMP9, OGN, procollagen C proteinase enhancer 1, phosphatidylethanol-amine-binding protein 1, pro-B-type natriuretic protein 1 to 108 (proBNP), peroxiredoxin 2, tissue inhibitor of proteinase 1 (TIMP1), and thrombospondin 2 were not normally distributed and were thus ln-transformed for further analyses. Figure 1 ). OGN (OR per SD increase in ln-transformed OGN, 1.50; 95% CI, 1.08-2.08; P=0.015) and NGAL/MMP9 (OR per SD increase in ln-transformed NGAL/MMP9, 1.38; 95% CI, 1.01-1.89; P=0.043) levels remained independently associated with MACE after additional adjustment for baseline CRP levels.
Discrimination
First, we evaluated a model containing conventional cardiovascular risk factors, including diabetes mellitus, hypertension, history of myocardial infarction, renal impairment, and indication for coronary angiography. This model displayed an area under the receiver operating characteristic curve of 0.67 ( Figure 2 ). When we added CRP to this model, it displayed an area under the receiver operating characteristic curve of 0.71 (P=0.41). Although not statistically significant, adding OGN (area under the receiver operating characteristic curve = 0.75; P=0.12 compared with model with conventional factors; P=0.47 compared with model with conventional factors+CRP) or NGAL/MMP9 (area under the receiver operating characteristic curve = 0.73; P=0. 19 compared with model with conventional factors; P=0.64 compared with model with conventional factors+CRP) slightly improved discriminatory ability of the model.
Reclassification
We examined whether adding OGN and NGAL/MMP9 to the conditional logistic regression model consisting of conventional cardiovascular risk factors and CRP level (as described above and in Table 3 ) results in correct reclassification of risk of MACE during follow-up (Table 4 ). OGN (net reclassification index = 0.29; 95% CI, 0.05-0.53; P=0.019) and NGAL/ MMP9 (net reclassification index = 0.44; 95% CI, 0.20-0.69; P<0.001) each significantly improved classification. Adding both OGN and NGAL/MMP9 resulted in a net reclassification index of 0.40 (95% CI, 0.17-0.64; P<0.001). 
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Discussion
This study investigated the associations between circulating plasma biomarkers, which were previously identified by proteomics or immunohistochemistry experiments in human carotid plaques and adverse cardiovascular outcome in patients undergoing coronary angiography. The prognostic value of the majority of these proteins, including OGN and NGAL/MMP9 complex, for MACE had not yet been investigated. Higher circulating OGN and NGAL/MMP9 complex levels were associated with incident MACE during the first year of follow-up, independently of conventional cardiovascular risk factors. Adding OGN or NGAL/MMP9 to a model containing conventional cardiovascular risk factors improved risk classification and discriminatory ability, although the latter was not statistically significant. These associations with incident MACE and improvements in predictive ability were independent of CRP.
In previous proteomic experiments, we have identified a series of novel potential markers of vulnerable atherosclerotic plaque. 8 We used human carotid atherosclerotic plaques, obtained from patients who underwent endarterectomy (n=80), which were classified as fibrotic plaques or hemorrhagic plaques according to the AHA classification and hemoglobin content. 8, 11, 12 We performed protein enrichment and mass spectrometry analysis and subsequently validation by Western blotting. We found that several tissue proteins within human atherosclerotic plaques were able to differentiate between vulnerable, hemorrhagic and stable, fibrolipidic lesions. 8 These proteins are known to be involved in various pathophysiological pathways, such as inflammation, cell integrity and arterial matrix remodeling (microfibril-associated glycoprotein 4, thrombospondin 2, OGN, procollagen C proteinase enhancer 1, TIMP1, aciculin, OGN), oxidative stress (DJ1, peroxiredoxin 2), and cell stress (heat shock protein 27). In the present study, we a priori hypothesized that circulating levels of these proteins may reflect presence of vulnerable plaques and may therefore also have prognostic value in patients with CAD.
OGN is a bone-associated glycoprotein but is also found to be a basic component of the vascular extracellular matrix. 13, 14 A previous study compared OGN expression in atherosclerotic Data are presented as mean±SD or as median (interquartile range). P values are obtained by using conditional logistic regression analyses. CABG indicates coronary artery bypass grafting; MI, myocardial infarction; MV, matching variable; and PCI, percutaneous coronary intervention.
*Cases: patients who experienced a major adverse cardiovascular event, including all-cause mortality, acute coronary syndrome, unplanned coronary revascularization, and stroke, within the first year of follow-up. †Control patients were matched on age, sex, and number of diseased coronary vessels.
lesions with normal vasculature in rabbits. 13 In atherosclerotic lesions, OGN was upregulated in activated endothelium and thick neointima and in the front edge of migrating smooth muscle cells. Another study demonstrated that OGN was substantially increased in the adventitia and neointima after balloon injury, implying a role for this protein in vessel matrix remodeling. 14 In line with these findings, close homologues of OGN, such as chicken proteoglycan Lb, were found to contribute to ordering of the matrix by interacting with collagens. 14, 15 Furthermore, OGN has the ability to bind transforming growth factor β, which has been shown to have significant effects on vascular smooth muscle cell behavior in vascular CI indicates confidence interval; CRP, C-reactive protein; DJ1, oncogene DJ1; HSP27, heat shock protein 27; MFAP4, microfibrilassociated glycoprotein 4; NGAL/MMP9, neutrophil gelatinase-associated lipocalin/matrix metalloproteinase 9; OGN, osteoglycin; OR, odds ratio; PCPE1, procollagen C proteinase enhancer 1; PEBP1, phosphatidylethanol-amine-binding protein 1; proBNP, pro-B-type natriuretic protein 1 to 108; PRX2, peroxiredoxin 2; TIMP1, tissue inhibitor of proteinase 1; and TSP2, thrombospondin 2.
*Odds ratio per SD increase in (ln-transformed) biomarker concentration. Conventional cardiovascular risk factors: diabetes mellitus, hypertension, smoking, dyslipidemia, history of myocardial infarction, renal impairment, and indication for coronary angiography. Data are presented as median (interquartile range). P values are obtained by using conditional logistic regression analyses. AU indicates arbitrary unit; CI, confidence interval; DJ1, oncogene DJ1; HSP27, heat shock protein 27; MFAP4, microfibril-associated glycoprotein 4; NGAL/MMP9, neutrophil gelatinase-associated lipocalin/matrix metalloproteinase 9; OGN, osteoglycin; OR, odds ratio; PCPE1, procollagen C proteinase enhancer 1; PEBP1, phosphatidylethanol-amine-binding protein 1; proBNP, pro-B-type natriuretic protein 1 to 108; PRX2, peroxiredoxin 2; TIMP1, tissue inhibitor of proteinase 1; and TSP2, thrombospondin 2.
*Cases: patients who experienced a major adverse cardiovascular event, including all-cause mortality, acute coronary syndrome, unplanned coronary revascularization, and stroke, within the first year of follow-up. †Control patients were matched on age, sex, and number of diseased coronary vessels. ‡Odds ratio per SD increase in (ln-transformed) biomarker concentration.
disease. 16 In our previous proteomics experiments, however, OGN was found to be downregulated in hemorrhagic plaques compared with fibrotic plaques. 8 The lower OGN levels suggested an altered strength and integrity of the vascular wall, which may make hemorrhagic plaques more prone to rupture. Its role as a prognostic circulating biomarker has also not been investigated yet. To our best knowledge, our study is the first to demonstrate that higher circulating OGN concentrations have prognostic value in patients with CAD. The seemingly contradictory results between the carotid proteomics study and the circulating levels in the present study may be because of global endothelial activation in acute conditions leading to the production of OGN, reflected by increased plasma levels.
Another explanation for the decreased OGN in hemorrhagic plaques is that it may be caused by elution of OGN into the circulation. Also, differences in carotid versus coronary atherothrombotic plaque biology may provide an explanation for this discrepancy. However, evidence that may support these hypotheses is currently lacking. Again, these results underscore that the precise role of (circulating) OGN requires further investigation. NGAL is a protein that is expressed in neutrophils, in the heart, in aorta tissue, and in low levels in the kidney. 17, 18 It is proposed to be a scavenger of bacterial products at sites of inflammation and a modulator of inflammation. 9 Although NGAL is well known as a biomarker of kidney injury, it has been shown that NGAL could also have a role in atherosclerotic disease. 9 NGAL is able to form a stable, biologically active complex with MMP9, preventing its degradation and thereby prolonging MMP9 activity. 11, 19 MMP9 is a protease of the MMP family that is capable of degrading a broad spectrum of extracellular matrix components and is held responsible for vascular remodeling and breakdown of the fibrous cap of atherosclerotic lesions leading to plaque vulnerability. 20 Several clinical studies have investigated the role of NGAL and MMP9 in cardiovascular disease, and associations of these markers with cardiovascular outcome have been found. 21, 22 Our results with regard to NGAL concur with these findings. However, although NGAL was univariately associated with adverse cardiovascular events in our study, this association was not independent of conventional cardiovascular risk factors. Renal insufficiency played a part in confounding of this association (post hoc analysis resulted in an OR adjusted for renal impairment only of 1.28 [0.97-1.68]; P=0.08) The contribution of this factor was probably enhanced by the tendency toward a higher prevalence of renal insufficiency in the patients that experienced MACE.
Conversely, limited data are available on NGAL/MMP9 complex in renal insufficiency and atherosclerosis. A previous study investigated NGAL/MMP9 complex in human atherosclerotic plaques and found that increased levels of NGAL/MMP9 complex were associated with high lipid content, high number of macrophages, high interleukin-6 and interleukin-8 levels, and low smooth muscle cell content in 122 human atherosclerotic lesions. 10 These results suggest that NGAL/MMP9 complex plays a part in the inflammation cascade leading to plaque instability. To our best knowledge, our study is the first to investigate circulating NGAL/MMP9 levels in a large clinical setting and to demonstrate that circulating NGAL/MMP9 levels have prognostic value in patients with CAD. Although NGAL/MMP9 was not significantly associated with MACE in univariate analysis (P=0.070), the association became statistically significant after adjustment for conventional risk factors (including renal insufficiency; P=0.042). Although lack of a univariable association may complicate interpretation of these findings, we think that it does not compromise clinical use. For the purpose of prognostication, biomarker information is traditionally evaluated in combination with the patient's clinical characteristics, and our study shows that NGAL/MMP9 significantly adds information to clinical characteristics, as demonstrated by an improvement of the net reclassification index. MMP9 is inhibited by TIMP1, a tissue inhibitor of metalloproteinases. TIMP1 was previously found to be an independent predictor of mortality and myocardial infarction in patients with CAD. 23 We also found an association between TIMP1 and incident MACE, but in our study this association was not independent of conventional cardiovascular risk factors.
The associations of OGN and NGAL/MMP9 complex with incident MACE and the improvements in predictive ability were independent of CRP levels. CRP is a well known prognostic marker of cardiovascular outcome in patients with known stable CAD and patients with acute coronary syndrome. [3] [4] [5] CRP is produced in the liver and reflects the overall inflammatory status of the patient 3-5 and thus does not distinguish particular causes of inflammation. Our results imply that OGN and NGAL/MMP9 may provide incremental value for prediction of cardiovascular risk on top of CRP.
The remaining biomarkers in this study did not show significant associations with MACE. Although natriuretic peptides are well known as markers for heart failure, it has been shown that natriuretic peptides also have prognostic information in patients with acute coronary syndrome. 24 In our study, proBNP tended to be associated with MACE in univariable analyses. We may have lacked power to detect a significant association between proBNP and MACE. With regard to heat shock protein 27, previous studies have rendered inconsistent results. With regard to thrombospondin 2, research was mainly focussed on single-nucleotide polymorphisms. The other proteins (aciculin, DJ1, microfibril-associated glycoprotein 4, procollagen C proteinase enhancer 1, phosphatidylethanol-amine-binding protein 1, and peroxiredoxin 2) have not been investigated as prognostic biomarkers in CAD patients before. An issue that warrants consideration in our study is the fact that we examined a total of 13 biomarkers, and if we were to account for multiple testing, our findings would lose statistical significance. However, our study was not data driven but hypothesis driven; the choice of biomarkers we investigated was based on our previous proteomics experiment. Therefore, accounting for multiple testing may not be fully justified. In any case, our findings should be considered as indicative of a potential association and merit validation in other, larger, studies.
In conclusion, OGN and NGAL/MMP9 are novel and promising prognostic biomarkers in patients with CAD. Both markers were previously found to be differentially expressed in vulnerable atherosclerotic plaques and are suggested to have important roles in arterial matrix remodeling and endothelial activation. Higher circulating OGN and NGAL/MMP9 levels were independently predictive for occurrence of MACE within 1 year after coronary angiography and displayed incremental value over conventional cardiovascular risk factors and CRP in terms of risk reclassification. Further studies are required to determine the precise pathophysiological role of OGN and NGAL/MMP9 in atherosclerosis and to confirm their roles as prognostic biomarkers of CAD.
